We gets lots of questions about how the patent system works for 505(b)(2)’s and how it relates (or not) to exclusivity provisions. A good friend and colleague who is an expert in patent law is going to join me on a webinar sponsored by DIA. It will be held April 22 from 11:00 to 12:30. [...]
Search
About
You are currently browsing the Drug Kennel weblog archives for the day Thursday, April 3rd, 2008.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Latest
- Failed 505(b)(2)?: Vivus’ Qnexa
- Will We Have Generic User Fees? Public Meeting To Be Held.
- Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?
- Generic Lovenox – 505j or 505(b)(2)
- New User Fees for 2011
- Still submitting paper ANDA applications?
- What should a license cost?
- Avandia: Who Won?
- Advisory Committee Meeting: Rosiglitazone
- The skinny on a potential new treatment of obesity